Therapy Areas: Oncology
Halozyme and GSK sign global drug‑delivery collaboration
...
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNP...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel...
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
...
ZYUS Life Sciences receives second US pain management patent
6 May 2026 - Canada-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialisation of novel non-opioid drug candidates for pa...
Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital
6 May 2026 - Citius Oncology Inc (Nasdaq:CTOR), a specialty biopharmaceutical company focused on the development and commercialisation of novel targeted oncology therapies, announced on Tuesday that i...